To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

计划入组 21 人 · 首次发布于 2015 年 12 月 8 日

Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma

计划入组 80 人 · 首次发布于 2011 年 12 月 8 日

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma

计划入组 17 人 · 首次发布于 2025 年 4 月 24 日

Orelabrutinib

C₂₆H₂₅N₃O₃ · Rx

Adebrelimab

Rx

panitumumab(Vectibix)

Rx

Toripalimab, Lenvatinib, and GEMOX Combination Shows Promise in Advanced Intrahepatic Cholangiocarcinoma

Glofitamab-GemOx Shows Survival Benefit in Phase 3 STARGLO Trial for R/R DLBCL, But FDA Advisory Committee Questions US Applicability

Atezolizumab, Bevacizumab, and GEMOX Combination Shows Promise in Advanced Biliary Tract Cancer